Elsevier Launches New Online Oncology Journal
London, May 31, 2006 – Elsevier, a world-leading healthcare and scientific publisher, is set to launch a new online-only oncology review journal. Update on Cancer Therapeutics, edited by Giuseppe Giaccone, Richard Schilsky and Paul Sondel, will be published quarterly, premiering in June 2006. Update on Cancer Therapeutics will provide a valuable new resource for clinicians seeking to stay current by publishing timely reviews on progress and achievements in clinical oncology and cancer therapeutics. Reviews focus on recent advances in the understanding of anti-cancer drugs, biological agents and the multi-disciplinary management of specific malignancies.
"We are committed to providing up-to-date, useful and clear reviews of the most important perspectives in oncology that have been recently identified," explained Editor, Paul Sondel. “Each issue of Update on Cancer Therapeutics reflects a spectrum of reviews presenting recent data, conclusions and recommendations that advance our understanding of anti-cancer drugs, specific malignancies and immunotherapy-host responses,” added Editor Richard Schilsky. "This format also enables user-friendly focused summaries of newer concepts and practices that complement both standard textbook chapters as well as initial reports of new findings," noted Editor Giuseppe Giaccone.
Subscribers will have full access to each issue as well as articles in press on the journal’s website, www.updateoncancer.com. Update on Cancer Therapeutics will also be accessible through Elsevier’s online database, ScienceDirect, the world's largest electronic collection of science, technology and medicine full text and bibliographic information.
# # #
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact:
Name Chelsea Drake
Phone +44 (0) 207 424 4276